EGFR and breast cancer: Importantly, synergistic effects were observed when this inhibitor was used in combination with other inhibitors targeting distinct regions of EGFR, namely, the extracellular ligand-binding domain and the intracellular kinase domain, leading to a significant enhancement in the suppression of breast cancer cell proliferation.